Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 462

Sort by

Sort Order Select

Journal Articles

Light Chain Multiple Myeloma - Clinical Characteristics and Outcomes

Blood (2024) 144 (Supplement 1): 6950.

https://doi.org/10.1182/blood-2024-208468

Published: 2024

Journal Articles

Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 83.

https://doi.org/10.1182/blood-2024-202098

Published: 2024

Journal Articles

Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4716.

https://doi.org/10.1182/blood-2024-211755

Published: 2024

Journal Articles

Radiomics-Based Biomarkers for Risk Stratification in Newly Diagnosed Multiple Myeloma

Jacob T Shreve, Michael D Howe, Emmanuel Contreras Guzman, Charalampos Charalampous, Wilson I. Gonsalves, Francis Buadi, Taxiarchis Kourelis, Suzanne R Hayman, Morie A. Gertz, Rafael Fonseca, S. Vincent Rajkumar, Surendra Dasari, Matthew P. Thorpe, Stephen Broski, Shaji Kumar, Moritz Binder

Blood (2024) 144 (Supplement 1): 4711.

https://doi.org/10.1182/blood-2024-202022

Published: 2024

Journal Articles

Development of a Three-Gene-Based Proliferation Score (3GPS) to Predict Proliferation Index in Newly Diagnosed Multiple Myeloma

Arwa Bohra, Surendra Dasari, Wilson I. Gonsalves, Prashant Kapoor, Saurabh Zanwar, Moritz Binder, Angela Dispenzieri, Michael M Timm, Dragan Jevremovic, S. Vincent Rajkumar, Shaji Kumar

Blood (2024) 144 (Supplement 1): 1945.

https://doi.org/10.1182/blood-2024-211902

Published: 2024

Journal Articles

Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients

Nadia Toumeh, Matthew James Rees, Morie A. Gertz, Angela Dispenzieri, Binoy Yohannan, Suheil Albert Atallah-Yunes, Prashant Kapoor, Taxiarchis Kourelis, Nelson Leung, Suzanne R Hayman, Francis Buadi, David Dingli, Joselle Cook, Rahma M Warsame, Moritz Binder, Wilson I. Gonsalves, S. Vincent Rajkumar, Shaji Kumar, Eli Muchtar

Blood (2024) 144 (Supplement 1): 3308.

https://doi.org/10.1182/blood-2024-202059

Published: 2024

Journal Articles

A Comparative Study of Plasma Cell Detection By Peripheral Smear and Peripheral Blood Flow Cytometry

Arwa Bohra, Rafla Hassan, Saurabh Zanwar, Dragan Jevremovic, Horatiu Olteanu, Wilson I. Gonsalves, Gregory Otteson, Pedro Horna, S. Vincent Rajkumar, Shaji Kumar

Blood (2024) 144 (Supplement 1): 3319.

https://doi.org/10.1182/blood-2024-211626

Published: 2024

Journal Articles

Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience

Blood (2024) 144 (Supplement 1): 1981.

https://doi.org/10.1182/blood-2024-208294

Published: 2024

Journal Articles

Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection

Alissa Visram, Dirk Larson, Aaron D Norman, Angela Dispenzieri, David L Murray, Robert A Kyle, S. Vincent Rajkumar, Susan L. Slager, Shaji K Kumar, Celine M. Vachon

Blood blood.2024025415.

https://doi.org/10.1182/blood.2024025415

Published: 2024

Includes: Supplemental data

Journal Articles

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Rahul Banerjee, Rachael Sexton, Andrew J. Cowan, Aaron S. Rosenberg, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji K Kumar, Angela Dispenzieri, Sagar Lonial, Brian G.M. Durie, Paul G. Richardson, Saad Z Usmani, Antje Hoering, Robert Z Orlowski

Blood blood.2024025939.

https://doi.org/10.1182/blood.2024025939

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

Blood (2023) 142 (22): 1871–1878.

https://doi.org/10.1182/blood.2023021187

Published: 2023

Includes: Supplemental data

Journal Articles

Impact of Dexamethasone (Dex) Dose Strength on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM): A Secondary Analysis of SWOG Studies S0777 and S1211

Rahul Banerjee, Rachael Sexton, Andrew J. Cowan, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji Kunnathu Kumar, Sagar Lonial, Bart Barlogie, Brian GM Durie, Saad Z Usmani, Antje Hoering, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 1066.

https://doi.org/10.1182/blood-2023-181744

Published: 2023

Journal Articles

Lymphoid Malignancy Risk with Rare Inherited Variants in Known Cancer Predisposition Genes

Blood (2023) 142 (Supplement 1): 2990.

https://doi.org/10.1182/blood-2023-182266

Published: 2023

Journal Articles

Performance of Newer Staging Systems for Myeloma in a Contemporary, Large Cohort of Patients in the United States

Ghulam Rehman Mohyuddin, Samuel M Rubinstein, Shaji Kunnathu Kumar, S. Vincent Rajkumar, Rafael Fonseca, Nadine Abdallah, Greg Calip, Xiaoyan Wang, Christina Parrinello, Doug Sborov

Blood (2023) 142 (Supplement 1): 1068.

https://doi.org/10.1182/blood-2023-185136

Published: 2023

Journal Articles

Standard-of-Care Bortezomib Dosing in Multiple Myeloma: An International Survey of Physicians

Rahul Banerjee, Gurbakhash Kaur, Bo Wang, Larry D. Anderson, Jr., Georgia McCaughan, Andrew J. Cowan, S. Vincent Rajkumar

Blood (2023) 142 (Supplement 1): 5073.

https://doi.org/10.1182/blood-2023-173772

Published: 2023

Journal Articles

High Prevalence of Iron Deficiency Among Daratumumab-Treated Newly Diagnosed Multiple Myeloma Patients

Blood (2023) 142 (Supplement 1): 3337.

https://doi.org/10.1182/blood-2023-184607

Published: 2023

Journal Articles

Cumulative Deficits Frailty Index and Relationship Status Predict Survival in Patients with Multiple Myeloma

Nadine Abdallah, Paul DiZona, Amanika Kumar, Betsy LaPlant, Terri Menser, Sarah Aug, Megan Weivoda, Joselle Cook, Francis Buadi, Suzanne R. Hayman, Angela Dispenzieri, Martha Lacy, Morie A Gertz, S. Vincent Rajkumar, Shaji Kunnathu Kumar

Blood (2023) 142 (Supplement 1): 1986.

https://doi.org/10.1182/blood-2023-187845

Published: 2023

Journal Articles

Single-Cell Dissection of Primary Quadruplet- and Triplet-Resistant Multiple Myeloma

Moritz Binder, Amelia Mazzone, Jenna A. Fernandez, Wazim Mohammed Ismail, S. Vincent Rajkumar, Alexandre Gaspar Maia, Shaji K Kumar

Blood (2022) 140 (Supplement 1): 9978–9979.

https://doi.org/10.1182/blood-2022-162679

Published: 2022

Journal Articles

AI-Enabled Screening for Drug Repurposing in Monoclonal Gammopathy of Undetermined Significance

Alexander J Ryu, Shaji K Kumar, Angela Dispenzieri, Robert A. Kyle, S. Vincent Rajkumar, Thomas C Kingsley

Blood (2022) 140 (Supplement 1): 7842–7843.

https://doi.org/10.1182/blood-2022-169376

Published: 2022

Journal Articles

Persistance or Reappearance of Serum Monoclonal Protein Detected By Mass Spectrometry Is a Major Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 2347–2348.

https://doi.org/10.1182/blood-2022-167430

Published: 2022

NARROW

Light Chain Multiple Myeloma - Clinical Characteristics and Outcomes

Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma

Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma

Radiomics-Based Biomarkers for Risk Stratification in Newly Diagnosed Multiple Myeloma

Development of a Three-Gene-Based Proliferation Score (3GPS) to Predict Proliferation Index in Newly Diagnosed Multiple Myeloma

Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients

A Comparative Study of Plasma Cell Detection By Peripheral Smear and Peripheral Blood Flow Cytometry

Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience

Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

Impact of Dexamethasone (Dex) Dose Strength on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM): A Secondary Analysis of SWOG Studies S0777 and S1211

Lymphoid Malignancy Risk with Rare Inherited Variants in Known Cancer Predisposition Genes

Performance of Newer Staging Systems for Myeloma in a Contemporary, Large Cohort of Patients in the United States

Standard-of-Care Bortezomib Dosing in Multiple Myeloma: An International Survey of Physicians

High Prevalence of Iron Deficiency Among Daratumumab-Treated Newly Diagnosed Multiple Myeloma Patients

Cumulative Deficits Frailty Index and Relationship Status Predict Survival in Patients with Multiple Myeloma

Single-Cell Dissection of Primary Quadruplet- and Triplet-Resistant Multiple Myeloma

AI-Enabled Screening for Drug Repurposing in Monoclonal Gammopathy of Undetermined Significance

Persistance or Reappearance of Serum Monoclonal Protein Detected By Mass Spectrometry Is a Major Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only